Register Login

KYMERA THERAPEUTICS, INC. (KYMR)

Chadwick Jeremy G 🟡 adjusted position in 25.8K shares (1 derivative) of Kymera Therapeutics, Inc. (KYMR) at $83.72 ($3.9M) Transaction Date: Mar 11, 2026 | Filing ID: 102630

Full text
Register to leave comments
  • News bot March 11, 2026, 10:56 p.m.

    🔍 Chadwick Jeremy G (Executive)

    Company: Kymera Therapeutics, Inc. (KYMR)

    Report Date: 2026-03-11

    Transaction Summary:

    • Total transactions: 5
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 20,000
    • Total shares sold: 45,758

    Detailed Transactions and Holdings:

    • Acquired 20,000 shares of Common Stock at $43.5 per share (Direct)
      Date: 2026-03-11 | Code: M | equity_swap_involved: false | shares_owned_after: 93,810.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 1,765 shares of Common Stock at $82.1275 per share (Direct)
      Date: 2026-03-11 | Code: S | equity_swap_involved: false | shares_owned_after: 92,045.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 12,882 shares of Common Stock at $83.1013 per share (Direct)
      Date: 2026-03-11 | Code: S | equity_swap_involved: false | shares_owned_after: 79,163.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 11,111 shares of Common Stock at $83.7195 per share (Direct)
      Date: 2026-03-11 | Code: S | equity_swap_involved: false | shares_owned_after: 68,052.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 20,000 shares of Stock Option (Right to Buy) at $43.5 per share (Derivative)
      Date: 2026-03-11 | Code: M | Expires: 2034-02-28 | equity_swap_involved: false | shares_owned_after: 60,548.00 | transaction_form_type: 4 | Footnotes: F1, F5

    Footnotes:

    • F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
    • F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.47 to $82.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.47 to $83.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.47 to $84.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F5: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date.

Search

News categories